QL1706
Clinical trials for QL1706 explained in plain language.
Never miss a new study
Get alerted when new QL1706 trials appear
Sign up with your email to follow new studies for QL1706, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug cocktail shows promise against tough esophageal cancer
Disease control Not yet recruitingThis study tests a new combination of drugs (QL1706 plus chemotherapy) as the first treatment for people with advanced or spreading esophageal cancer. About 50 adults who have not had prior treatment will receive the combo to see if it shrinks tumors and how long it keeps the can…
Matched conditions: QL1706
Phase: PHASE2 • Sponsor: The First Affiliated Hospital of Henan University of Science and Technology • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New breast cancer trial aims to spare heart toxicity with smart drug strategy
Disease control Not yet recruitingThis Phase 2 trial tests a new antibody drug (QL1706) combined with chemotherapy in 40 people with early triple-negative breast cancer. The treatment is tailored based on how the tumor responds after initial cycles, with the goal of avoiding certain heart-damaging drugs if possib…
Matched conditions: QL1706
Phase: PHASE2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New drug cocktail aims to shrink colon tumors before surgery
Disease control Not yet recruitingThis study tests whether a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus chemotherapy can shrink tumors before surgery in people with stage III colon cancer that is microsatellite stable (pMMR/MSS). About 21 participants will receive four cycles of th…
Matched conditions: QL1706
Phase: PHASE2 • Sponsor: Qilu Hospital of Shandong University • Aim: Disease control
Last updated Jun 26, 2026 14:11 UTC